Adam R. Levy, Chief Executive Officer of NEXGEL, INC. (NASDAQ:NXGL), recently reported multiple transactions involving the sale of the company's common stock. Over the course of late May, Mr. Levy executed three distinct sales, totaling 13,000 shares. These dispositions occurred between May 27 and May 29, 2026, generating proceeds amounting to approximately $7,834.
The details of these open market sales illustrate the structured nature of the insider activity. On May 27th, Mr. Levy sold 3,000 shares at a price point of $0.5975 per share. The following day, May 28th, saw the disposition of 7,000 shares. This sale was based on a weighted average price of $0.6058 per share, with individual transactions during that period ranging from $0.5958 to $0.6133 per share. Completing the series of sales, a final transaction took place on May 29th, involving the sale of another 3,000 shares at a price of $0.6003 each.
Collectively, these transactions spanned an overall trading range between $0.5975 and $0.6058 per share. Following these reported insider sales, Mr. Levy's direct holdings of NEXGEL common stock were recorded at 344,692 shares.
These executive transactions are contextualized against the backdrop of recent market performance for NEXGEL. The company’s stock has shown an increase of nearly 13% over the past week. However, a longer-term view reveals that the shares have declined by 72% over the last year. Furthermore, analysis from InvestingPro suggests that, at current valuation levels, the stock may be considered undervalued, noting the availability of ten additional ProTips for subscribers.
Beyond the insider trading activity and market metrics, NEXGEL Inc. has provided several operational updates. The company released its financial results for the first quarter of 2026. These results indicated a net loss per share of -0.11 USD. Revenue reached $2.65 million USD, representing a decline of 5.7% when compared to the figures from the previous year.
Despite the reported decrease in revenue, NEXGEL signaled expectations of significant future growth. This optimism is tied directly to the firm's recent acquisition of BioNX. Furthermore, Nexgel announced positive findings from a clinical study concerning its hydrogel patch. The research demonstrated a notable 95.6% reduction in plume concentration during laser hair removal procedures. This study was conducted at the Florida Clinical Research Center by plastic surgeons Dr. Barry DiBernardo and Dr. Jason Pozner, and it received funding from Innovative Optics. The findings were formally published in the academic journal Lasers in Surgery and Medicine.
These combined developments underscore NEXGEL's multifaceted strategy, encompassing efforts to advance its product pipeline through clinical validation and executing strategic corporate expansions via acquisitions.
Risks
- The stock has declined by 72% over the past year, suggesting significant prior volatility or market skepticism.
- Q1 2026 financials showed a net loss per share of -0.11 USD and a 5.7% decline in revenue compared to the previous year.
- The company's overall financial health is currently offset by recent losses, despite future growth projections from acquisitions.
More from Insider Trading
Risks
- The stock has declined by 72% over the past year, suggesting significant prior volatility or market skepticism.
- Q1 2026 financials showed a net loss per share of -0.11 USD and a 5.7% decline in revenue compared to the previous year.
- The company's overall financial health is currently offset by recent losses, despite future growth projections from acquisitions.